Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × nimotuzumab × 1 year × Clear all

Phase

Phase 2 11 Phase 3 5 Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 1 Adenocarcinoma 1

Interventions

Cisplatin 25 pembrolizumab 24 Carboplatin 19 Magnetic Resonance Spectroscopy 17 Gemcitabine 16 Paclitaxel 15 Drug Therapy 15 Oxaliplatin 14 Cyclophosphamide 14 Specimen Handling 12 Radiotherapy 12 Nivolumab 12 Doxorubicin 12 Capecitabine 12 atezolizumab 11 Bevacizumab 11 Docetaxel 10 Vincristine 9 Trastuzumab 9 Radiation 9 Pemetrexed 9 Fluorouracil 9 Dexamethasone 9 venetoclax 8 Prednisone 8 Ipilimumab 8 Cytarabine 8 Leucovorin 7 Etoposide 7 130-nm albumin-bound paclitaxel 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01249352 2025-03-31

NICE

Eurofarma Laboratorios S.A.

Phase 2/3 Completed

Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡